Feedback / Questions
nesvacumab (REGN910) - Regeneron
Nesvacumab: "Ocular and systemic safety consistent with IAI monotherapy"
(Regeneron Pharmaceuticals)
-
Feb 13, 2018 -
Angiogenesis Conference 2018
P2 data
•
Diabetic Macular Edema • Ophthalmology
http://files.shareholder.com/downloads/REGN/5692021876x0x971130/EAACA718-5F6E-4E70-90BE-181D76EB0180/Regeneron_Brown_RUBY_Angiogenesis_2018.pdf
Feb 13, 2018
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious